Bausch Health Companies - BHC Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Hold
Consensus Price Target: $8.88
Forecasted Upside: 8.50%
Number of Analysts: 4
Breakdown:
0 Sell Ratings
4 Hold Ratings
0 Buy Ratings
0 Strong Buy Ratings

^$8.18 As of 06/2/2023 01:09 PM ET

▼ -0.02 (-0.24%)

1 month | 3 months | 12 months

Get New Bausch Health Companies Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for BHC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BHC

^$8.88

▲ +8.50% Upside Potential

This price target is based on 4 analysts offering 12 month price targets for Bausch Health Companies in the last 3 months. The average price target is $8.88, with a high forecast of $12.00 and a low forecast of $6.00. The average price target represents a 8.50% upside from the last price of $8.18.

Current Consensus is Hold

The current consensus among 4 investment analysts is to hold stock in Bausch Health Companies. This rating has held steady since July 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
3 buy ratings
5 hold ratings
1 sell ratings

Ratings as of

12/9/2021

0 strong buy ratings
3 buy ratings
3 hold ratings
1 sell ratings

Ratings as of

3/9/2022

0 strong buy ratings
3 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

6/7/2022

0 strong buy ratings
1 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

9/5/2022

0 strong buy ratings
0 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

12/4/2022

0 strong buy ratings
0 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

3/4/2023

0 strong buy ratings
0 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

5/3/2023

0 strong buy ratings
0 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

6/2/2023

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
5/22/2023	Jefferies Financial Group	Boost Target		$7.00 ➝ $9.50	Low
9/9/2022	Piper Sandler	Lower Target	Neutral	$7.00 ➝ $6.00	Low
9/1/2022	Royal Bank of Canada	Boost Target	Sector Perform	$4.50 ➝ $8.00	Low
8/10/2022	Royal Bank of Canada	Lower Target	Sector Perform	$5.00 ➝ $4.50	Low
7/29/2022	Royal Bank of Canada	Downgrade	Outperform ➝ Sector Perform	$12.00 ➝ $5.00	Low
7/28/2022	Truist Financial	Downgrade	Buy ➝ Hold		Low
7/28/2022	JPMorgan Chase & Co.	Downgrade	Overweight ➝ Neutral		Low
6/13/2022	JPMorgan Chase & Co.	Initiated Coverage	Overweight	$12.00	High
5/26/2022	Piper Sandler	Lower Target		$27.00 ➝ $7.00	Low
5/15/2022	Royal Bank of Canada	Lower Target	Outperform	$21.00 ➝ $17.00	Low
5/11/2022	BMO Capital Markets	Lower Target		$26.00 ➝ $15.00	High
5/11/2022	Bank of America	Lower Target		$25.00 ➝ $12.00	High
5/9/2022	Royal Bank of Canada	Lower Target	Outperform	$32.00 ➝ $21.00	High
2/1/2022	Royal Bank of Canada	Lower Target	Outperform	$40.00 ➝ $34.00	Low
11/8/2021	BMO Capital Markets	Reiterated Rating	Hold		Low
11/3/2021	Royal Bank of Canada	Lower Target	Outperform	$41.00 ➝ $40.00	High
10/1/2021	Jefferies Financial Group	Reiterated Rating	Buy		High
8/4/2021	Barclays	Lower Target	In-Line ➝ Overweight	$35.00 ➝ $31.00	High
7/8/2021	HC Wainwright	Reiterated Rating	Buy		Low
5/5/2021	Royal Bank of Canada	Lower Target	Outperform	$42.00 ➝ $41.00	Low
3/30/2021	Bank of America	Reiterated Rating	Neutral ➝ Underperform	$27.00	Low
3/24/2021	Bank of America	Downgrade	Neutral ➝ Underperform	$27.00	Low
3/16/2021	HC Wainwright	Boost Target	Buy	$50.00 ➝ $55.00	Low
3/14/2021	JPMorgan Chase & Co.	Reiterated Rating	Buy	$38.00	Low
3/2/2021	Citigroup	Boost Target		$32.00 ➝ $37.00	Low
2/26/2021	Morgan Stanley	Boost Target	Equal Weight	$22.00 ➝ $35.00	Medium
2/25/2021	Barclays	Boost Target	Overweight	$27.00 ➝ $35.00	Low
2/17/2021	Royal Bank of Canada	Upgrade	Sector Perform ➝ Outperform	$26.00 ➝ $42.00	Low
2/16/2021	JPMorgan Chase & Co.	Boost Target	Overweight	$32.00 ➝ $38.00	Low
1/22/2021	Piper Sandler	Downgrade	Overweight ➝ Neutral	$25.00 ➝ $30.00	Low
1/15/2021	Jefferies Financial Group	Boost Target		$27.00 ➝ $33.00	Low
11/5/2020	Piper Sandler	Lower Target	Overweight	$26.00 ➝ $25.00	Low
10/28/2020	Wells Fargo & Company	Lower Target	Equal Weight	$18.00 ➝ $17.00	Medium
10/26/2020	Barclays	Boost Target	Overweight	$28.00 ➝ $29.00	High
9/17/2020	Bank of America	Upgrade	Underperform ➝ Neutral	$19.00	High
8/24/2020	HC Wainwright	Reiterated Rating	Buy	$64.00 ➝ $50.00	High
8/19/2020	Piper Sandler	Lower Target	Overweight	$32.00 ➝ $26.00	High
8/10/2020	Royal Bank of Canada	Boost Target	Sector Perform	$23.00 ➝ $26.00	Low
8/10/2020	Citigroup	Lower Target	Buy	$27.00 ➝ $26.00	Medium
8/7/2020	Barclays	Boost Target	Overweight	$25.00 ➝ $28.00	High
7/31/2020	Royal Bank of Canada	Lower Target	Sector Perform	$24.00 ➝ $23.00	Low
7/7/2020	Bank of America	Boost Target	Underperform	$12.00 ➝ $14.00	High
6/17/2020	HC Wainwright	Boost Target	Buy	$50.00 ➝ $64.00	Medium
5/8/2020	Cfra	Lower Target	Hold	$28.00 ➝ $18.00	Low
5/8/2020	SunTrust Banks	Lower Target	Buy	$25.00 ➝ $24.00	High
5/8/2020	Royal Bank of Canada	Lower Target	Sector Perform	$25.00 ➝ $24.00	High
4/30/2020	Wells Fargo & Company	Boost Target	Equal Weight	$17.00 ➝ $18.00	Low
4/28/2020	HC Wainwright	Reiterated Rating	Buy	$50.00	Medium
4/28/2020	Royal Bank of Canada	Lower Target	Sector Perform	$26.00 ➝ $25.00	High
4/24/2020	Citigroup	Initiated Coverage	Buy	$30.00	High
4/23/2020	Jefferies Financial Group	Lower Target	Buy	$35.00 ➝ $27.00	Medium
4/2/2020	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight		Low
3/23/2020	HC Wainwright	Lower Target	Buy	$60.00 ➝ $50.00	High
3/23/2020	Wells Fargo & Company	Lower Target	Equal Weight	$32.00 ➝ $17.00	High
3/17/2020	Royal Bank of Canada	Lower Target	Sector Perform	$31.00 ➝ $26.00	Medium
2/20/2020	Royal Bank of Canada	Lower Target	Sector Perform	$33.00 ➝ $31.00	High
2/20/2020	SunTrust Banks	Lower Target	Buy	$32.00 ➝ $31.00	Low
2/19/2020	Cowen	Reiterated Rating	Buy	$40.00	Low
2/19/2020	Guggenheim	Reiterated Rating	Buy	$36.00	Low
2/11/2020	Morgan Stanley	Lower Target	Overweight	$34.00 ➝ $32.00	Low
2/4/2020	Royal Bank of Canada	Boost Target	Sector Perform	$31.00 ➝ $33.00	High
1/29/2020	Wolfe Research	Downgrade	Outperform ➝ Peer Perform		Low
1/26/2020	Barclays	Reiterated Rating	Buy	$33.00	Low
1/22/2020	Wells Fargo & Company	Upgrade	Underweight ➝ Equal Weight	$32.00	Medium
12/30/2019	Piper Jaffray Companies	Boost Target	Neutral ➝ Overweight	$30.00 ➝ $39.00	Medium
12/23/2019	HC Wainwright	Reiterated Rating	Buy	$60.00	N/A
12/12/2019	JPMorgan Chase & Co.	Upgrade	Neutral ➝ Overweight	$32.00 ➝ $38.00	High
12/2/2019	HC Wainwright	Reiterated Rating	Buy	$54.00 ➝ $60.00	Low
12/2/2019	The Goldman Sachs Group	Initiated Coverage	Neutral	$30.00	Low
11/5/2019	Barclays	Boost Target	Overweight	$28.00 ➝ $30.00	Low
10/25/2019	Cowen	Initiated Coverage	Outperform	$35.00	Medium
9/17/2019	Wells Fargo & Company	Reiterated Rating	Sell		Low
9/12/2019	Guggenheim	Initiated Coverage	Buy	$30.00	High
8/15/2019	TD Securities	Upgrade	Hold ➝ Buy	$28.00	Medium
8/7/2019	HC Wainwright	Boost Target	Market Perform ➝ Buy	$50.00 ➝ $54.00	Low
7/29/2019	HC Wainwright	Lower Target	Buy	$58.00 ➝ $50.00	Low
7/19/2019	Wolfe Research	Initiated Coverage	Outperform ➝ Outperform	$31.00	Low
7/15/2019	Wells Fargo & Company	Reiterated Rating	Sell		Low
7/8/2019	Barclays	Set Target	Buy	$28.00	Low
6/20/2019	Mizuho	Set Target	Buy	$45.00	Medium
6/11/2019	Piper Jaffray Companies	Set Target	Buy	$29.00	Medium
6/11/2019	Barclays	Reiterated Rating	Overweight ➝ Overweight	$28.00	Medium
5/31/2019	Cantor Fitzgerald	Set Target	Buy	$32.00	Low
5/17/2019	Wells Fargo & Company	Set Target	Sell	$9.00	Low
5/13/2019	JPMorgan Chase & Co.	Upgrade	Underweight ➝ Neutral	$24.80	Low
5/7/2019	Mizuho	Boost Target	Buy	$41.00 ➝ $45.00	Low
4/25/2019	Cantor Fitzgerald	Reiterated Rating	Buy	$32.00	Low
4/2/2019	Piper Jaffray Companies	Set Target	Buy	$28.00	Low
3/20/2019	Bank of America	Reiterated Rating	Underperform	$18.00	High
3/19/2019	SunTrust Banks	Initiated Coverage	Buy ➝ Buy	$30.00	High
3/18/2019	Mizuho	Boost Target	Buy	$39.00 ➝ $41.00	High
2/28/2019	HC Wainwright	Reiterated Rating	Buy		Medium
2/19/2019	Wells Fargo & Company	Boost Target	Sell ➝ Underperform	$9.00 ➝ $25.19	High
1/6/2019	Mizuho	Reiterated Rating	Buy	$39.00	High
1/2/2019	UBS Group	Upgrade	Buy		High
1/1/2019	Piper Jaffray Companies	Upgrade	Neutral ➝ Overweight	$27.00	High
12/17/2018	Morgan Stanley	Set Target	Buy	$32.00	High
12/14/2018	HC Wainwright	Upgrade	Average ➝ Buy		Low
12/12/2018	Wells Fargo & Company	Set Target	Sell	$9.00	Medium
11/30/2018	Mizuho	Boost Target	Buy ➝ Buy	$35.00 ➝ $38.00	Low
11/13/2018	BMO Capital Markets	Reiterated Rating	Hold	$26.00	Medium
11/7/2018	TD Securities	Boost Target	Hold	$24.00 ➝ $28.00	Low
11/7/2018	Royal Bank of Canada	Boost Target	Hold	$30.00 ➝ $31.00	Medium
11/6/2018	Cantor Fitzgerald	Reiterated Rating	Buy		N/A
11/5/2018	Morgan Stanley	Upgrade	Equal Weight ➝ Overweight	$32.00	High
10/15/2018	HC Wainwright	Set Target	Hold	$25.00	Low
10/8/2018	HC Wainwright	Set Target	Hold	$25.00	Medium
10/8/2018	Mizuho	Reiterated Rating	Buy	$35.00	Medium
10/8/2018	Royal Bank of Canada	Set Target	Sector Perform ➝ Hold	$26.00 ➝ $30.00	Medium
9/13/2018	HC Wainwright	Reiterated Rating	Hold	$25.00	High
9/13/2018	Piper Jaffray Companies	Upgrade	Underweight ➝ Neutral	$16.00 ➝ $19.00	High
9/12/2018	Deutsche Bank Aktiengesellschaft	Set Target	Buy	$30.00	High
9/12/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$32.00	High
8/31/2018	HC Wainwright	Reiterated Rating	Hold	$20.00	Medium
8/13/2018	BMO Capital Markets	Boost Target	Market Perform ➝ Market Perform	$20.00 ➝ $22.00	Medium
8/8/2018	Royal Bank of Canada	Boost Target	Hold	$25.00 ➝ $26.00	Low
8/8/2018	JPMorgan Chase & Co.	Boost Target	Underweight	$18.00	Low
8/7/2018	Piper Jaffray Companies	Set Target	Sell	$16.00	Low
8/7/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$32.00	Low
8/7/2018	Mizuho	Reiterated Rating	Buy	$31.00	High
8/6/2018	Wells Fargo & Company	Reiterated Rating	Sell		High
7/23/2018	Piper Jaffray Companies	Set Target	Sell	$13.00	Low
6/29/2018	Deutsche Bank Aktiengesellschaft	Reiterated Rating	Buy		Low
6/29/2018	Mizuho	Reiterated Rating	Buy	$31.00	Medium
6/22/2018	TD Securities	Downgrade	Buy ➝ Hold	$24.00	Low
6/20/2018	HC Wainwright	Reiterated Rating	Hold	$20.00	Low
6/6/2018	Barclays	Upgrade	Equal Weight ➝ Overweight	$20.00 ➝ $34.00	High
6/5/2018	HC Wainwright	Set Target	Hold	$20.00	High

(Data available from 6/2/2018 forward)

News Sentiment Rating

0.51 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

2 very positive mentions
10 positive mentions
1 negative mentions
1 very negative mentions

Mentions as of

11/4/2022

3 very positive mentions
8 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

12/4/2022

1 very positive mentions
3 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

1/3/2023

5 very positive mentions
5 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

2/2/2023

8 very positive mentions
9 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

3/4/2023

4 very positive mentions
3 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

4/3/2023

7 very positive mentions
8 positive mentions
1 negative mentions
2 very negative mentions

Mentions as of

5/3/2023

9 very positive mentions
21 positive mentions
3 negative mentions
1 very negative mentions

Mentions as of

6/2/2023

Current Sentiment

Recent Stories by Sentiment

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, with the exception of sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refer to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologics, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.

Today's Range

Now: $8.18

$8.09

$8.38

50 Day Range

MA: $7.38

$5.72

$8.80

52 Week Range

Now: $8.18

$4.00

$10.23

Volume

831,376 shs

Average Volume

4,554,822 shs

Market Capitalization

$2.96 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.95

Frequently Asked Questions

What sell-side analysts currently cover shares of Bausch Health Companies?: The following Wall Street analysts have issued research reports on Bausch Health Companies in the last year: Jefferies Financial Group Inc., JPMorgan Chase & Co., Piper Sandler, Royal Bank of Canada, StockNews.com, and Truist Financial Co..
View the latest analyst ratings for BHC.
What is the current price target for Bausch Health Companies?: 4 Wall Street analysts have set twelve-month price targets for Bausch Health Companies in the last year. Their average twelve-month price target is $8.88, suggesting a possible upside of 8.5%. JPMorgan Chase & Co. has the highest price target set, predicting BHC will reach $12.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $6.00 for Bausch Health Companies in the next year.
View the latest price targets for BHC.
What is the current consensus analyst rating for Bausch Health Companies?: Bausch Health Companies currently has 4 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in BHC, but not buy more shares or sell existing shares.
View the latest ratings for BHC.
What other companies compete with Bausch Health Companies?: Other companies that are similar to Bausch Health Companies include Sage Therapeutics, Axsome Therapeutics, Galapagos, Zai Lab and Amicus Therapeutics. Learn More about companies similar to Bausch Health Companies.
How do I contact Bausch Health Companies' investor relations team?: Bausch Health Companies' physical mailing address is 2150 ST. ELZEAR BLVD. WEST, LAVAL A8, H7L 4A8. The company's listed phone number is (514) 744-6792 and its investor relations email address is [email protected]. The official website for Bausch Health Companies is www.bauschhealth.com. Learn More about contacing Bausch Health Companies investor relations.

Bausch Health Companies - BHC Stock Price Target and Predictions

Analyst Price Target for BHC

Current Consensus is Hold

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.51 (Buy)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Bausch Health Companies?

What is the current price target for Bausch Health Companies?

What is the current consensus analyst rating for Bausch Health Companies?

What other companies compete with Bausch Health Companies?

How do I contact Bausch Health Companies' investor relations team?